Jazz Pharmaceuticals plc (JAZZ)
Automate Your Wheel Strategy on JAZZ
With Tiblio's Option Bot, you can configure your own wheel strategy including JAZZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JAZZ
- Rev/Share 68.5026
- Book/Share 65.2272
- PB 2.5589
- Debt/Equity 0.2735
- CurrentRatio 1.6516
- ROIC -0.0256
- MktCap 10142260780.0
- FreeCF/Share 22.02
- PFCF 7.5885
- PE -27.4931
- Debt/Assets 0.0953
- DivYield 0
- ROE -0.0925
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JAZZ | UBS | Buy | Neutral | -- | $188 | Nov. 24, 2025 |
| Initiation | JAZZ | Deutsche Bank | -- | Buy | -- | $152 | July 15, 2025 |
| Upgrade | JAZZ | UBS | Neutral | Buy | $145 | $179 | March 7, 2025 |
| Downgrade | JAZZ | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Feb. 26, 2025 |
| Upgrade | JAZZ | Wells Fargo | Equal Weight | Overweight | $130 | $170 | Feb. 13, 2025 |
| Upgrade | JAZZ | Morgan Stanley | Equal Weight | Overweight | $140 | $175 | Dec. 12, 2024 |
News
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Read More
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Published: December 05, 2025 by: PRNewsWire
Sentiment: Neutral
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, including four late-breaking abstracts, underscore Jazz's continued commitment to the epilepsy community and advancing the comprehensive treatment for rare forms of epilepsy For U.S. media and investors only DUBLIN , Dec. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts, including four that are late-breaking, will be presented on Epidiolex® (cannabidiol) at the American Epilepsy Society (AES) 2025 Annual Meeting, being held December 5-9, 2025, in Atlanta, Georgia. Notable …
Read More
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.
Read More
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
Read More
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive
Jazz Pharmaceuticals plc surged over 20% after positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer. JAZZ's diversified portfolio, strong Q3 earnings, and upgraded 2025 revenue guidance support its current double-digit billion valuation. Key risks include upcoming patent expiries, new competition for Xywav, and uncertainty around long-term profitability and revenue replacement.
Read More
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive
Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in combination with Tevimbra and chemotherapy outperformed trastuzumab plus chemotherapy, and the triple combination achieved statistically significant overall survival benefit. The GEA indication represents a $2 billion+ a year opportunity for JAZZ and a $300 million opportunity for BeOne, and ZYME stands to benefit by receiving royalties from both partners.
Read More
Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Read More
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
Read More
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
Published: October 21, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it has entered into a research collaboration and drug supply agreement with Jazz Pharmaceuticals. Under the agreement, Jazz will provide zanidatamab (Ziihera®), a HER2-targeted bispecific antibody, at no cost to Iambic for evaluation in combination with IAM1363, Iambic's brain-penetrant HER2 small-molec.
Read More
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.
Read More
Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants Amal Melhem-Bertrandt Philip Johnson - Executive VP & CFO Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Thank you very much for joining us today. My name is Mohit Bansal.
Read More
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
Read More
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an overall response rate in patients with progressive disease following prior therapy Company to host investor webcast on August 27, 2025 For U.S. media and investors only DUBLIN , Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an …
Read More
US FDA approves Jazz Pharma's drug for rare brain tumor
Published: August 06, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one year and older.
Read More
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.
Read More
Is JAZZ Stock Undervalued At $110?
Published: July 07, 2025 by: Forbes
Sentiment: Positive
Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European Commission Marketing Authorization for Ziihera (zanidatamab) aimed at advanced HER2-Positive Biliary Tract Cancer. Ziihera is the first HER2-targeted therapy approved in the EU for this condition, with anticipated peak annual sales surpassing $2 billion.
Read More
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
Published: July 07, 2025 by: Seeking Alpha
Sentiment: Positive
In recent months, Jazz Pharmaceuticals plc has remained a stock that has seen some decline in attention from retail investors. This comes amid the potential approval of Zepzelca in combination with Tecentriq as a therapy for first-line extensive-stage small cell lung cancer. Meanwhile, the crown jewel of Jazz Pharmaceuticals' oncology franchise is Ziihera, which is superior in efficacy to chemotherapy drugs and Enhertu in the treatment of biliary tract cancer and more.
Read More
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Read More
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology For U.S. media and investors only DUBLIN , June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating Ziihera® (zanidatamab-hrii), a dual HER2-targeted bispecific antibody, in combination with chemotherapy for the investigational use in first-line HER2-positive (IHC 3+ or IHC …
Read More
Jazz Pharmaceuticals: One Step Forward, One Back
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compete with Jazz's Xywav in idiopathic hypersomnia. There are three potential catalysts for the oncology business in the second half of the year that should translate to a revenue growth inflection point in 2026.
Read More
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
Read More
Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D and Chief Medical Officer Phil Johnson - Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Jessica Fye - JP Morgan David Amsellem - Piper Sandler Marc Goodman - Leerink Partners. Annabel Samimy - Stifle Joseph Thome - TD Cowen Gregory Renza - RBC Capital Markets …
Read More
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $1.68 per share, missing the Zacks Consensus Estimate of $4.51 per share. This compares to earnings of $2.68 per share a year ago.
Read More
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
Read More
3 Unconventional Cannabis Stocks to Watch in 2025
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
Read More
About Jazz Pharmaceuticals plc (JAZZ)
- IPO Date 2007-06-01
- Website https://www.jazzpharma.com
- Industry Biotechnology
- CEO Renee D. Gala
- Employees 2800